Treatment of Primary Gastric Lymphoma in Gastric MALT-Type Lymphoma without Helicobacter pylori Infection
This protocol covers the management of primary gastric MALT-type lymphoma in patients where Helicobacter pylori infection is absent — a subgroup in which antibiotic eradication therapy is not applicable and a distinct treatment pathway applies.
Clinical Scenario
Gastric MALT-type lymphoma without Helicobacter pylori infection. Almost 10% of MALT lymphomas are unrelated to H. pylori infection, and the pathogenesis in this group remains unclear.
Treatment Approach
When H. pylori eradication is not an option, systemic immunotherapy — centred on rituximab-based regimens — is a key component of the approach. The complete regimen options, sequencing, and clinical criteria are available in the full protocol.
Treatment Goal
The primary clinical objective is complete remission of the gastric MALT lymphoma.
References
- Almost 10% of MALT lymphomas are unrelated to H pylori infection, and the pathogenesis remains unclear.
- Patients with localized disease, who did not respond to antibiotic therapy or radiation therapy, should be considered for systemic chemotherapy.
- R–bendamustine seems to be highly effective and well tolerated.
- In this trial, the combination of the 2 drugs resulted in improved remission quality measured by complete remission rate and translated into significantly prolonged EFS.
View source ↗